Skip to main content
Premium Trial:

Request an Annual Quote

LGC Clinical Diagnostics SeraSeq ctDNA Lymphoma Mutation Mix

LGC Clinical Diagnostics has launched the SeraSeq ctDNA Lymphoma Mutation Mix which, in conjunction with the SeraSeq Lymphoma DNA Mutation Mix and FFPE Lymphoma Reference Material, establishes a complete set of lymphoid reference materials for next-generation sequencing-based lymphoid assay development, the company said. Together, the materials include clinically important SNVs, INDELs, and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays, according to a company product sheet.